DE
Merck Pipeline
| Drug | Indication | Phase |
|---|---|---|
| KEYTRUDA (pembrolizumab) | Adjuvant Non-Small Cell Lung Cancer (NSCLC) | Phase 3 |
| V116 | Pneumococcal Disease (Adult) | Phase 3 |
| MK-0616 | Hypercholesterolemia | Phase 3 |
| Patritumab Deruxtecan | Metastatic EGFR-mutated NSCLC | Phase 3 |
| V940 (mRNA-4157) | Adjuvant Melanoma | Phase 3 |
| Sotatercept | Pulmonary Arterial Hypertension (PAH) | Phase 3 |
| MK-1022 (Nemtabrutinib) | Relapsed/Refractory CLL/SLL and MCL | Phase 3 |
| MK-5684 | Metastatic Castration-Resistant Prostate Cancer | Phase 3 |
Leadership Team at Merck
RM
Robert M. Davis
Chairman, President & CEO
CL
Caroline Litchfield
EVP & Chief Financial Officer
DD
Dr. Dean Y. Li
President, Merck Research Laboratories
DJ
Dr. Julie L. Gerberding
EVP & Chief Patient Officer
SC
Sanat Chattopadhyay
EVP & President, Manufacturing Division
JZ
Jennifer Zachary
EVP, General Counsel & Corporate Secretary